BSX vs NVCR: Which Is the Better Buy in 2026?

Last updated October 2026

Short answer

BSX is the larger of the two ($64.33B market cap): the incumbent the market prices for continued execution (13.15x forward earnings, beta 0.57). NVCR is the smaller challenger ($1.64B), priced similarly on forward earnings (-17.45x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

BSX vs NVCR: the tie-breaker metrics

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Metric	BSX	NVCR	What it tells you
Market cap	$64.33B	$1.64B	Size. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E	13.15	-17.45	Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta	0.57	0.99	Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range	5% of range	37% of range	Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book	2.58	4.85	How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how BSX and NVCR affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BSX and NVCR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BSX and NVCR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Boston Scientific Corporation (BSX) do?

Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. It reports through two broad segments: Cardiovascular, which houses the electrophysiology business (led by the Farapulse pulsed field ablation system) and the Watchman left-atrial-appendage closure franchise, and MedSurg, which spans endoscopy, urology, and neuromodulation. The company sells into hospitals and physicians across roughly 130 countries and competes at the leading edge of catheter-based and device-based procedures that substitute for more invasive surgery.

Full BSX guide

What does NovoCure Ltd (NVCR) do?

NovoCure Ltd. (Nasdaq: NVCR) is an oncology medical device company built around Tumor Treating Fields (TTFields), a therapy that delivers low-intensity alternating electric fields through wearable arrays to disrupt cancer cell division. Its FDA-approved Optune platform spans Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax, approved in February 2026 for locally advanced pancreatic cancer. Optune Pax has since launched in Germany under a CE mark and on October 1, 2026 received approval in Japan for unresectable locally advanced pancreatic cancer. The company reported full-year 2025 net revenue of about $655 million (up ~8%) with roughly 4,620 active patients on therapy at year-end. Frank Leonard became chief executive in late 2025.

Full NVCR guide

BSX vs NVCR: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

BSX drivers: Farapulse and the Pulsed Field Ablation Wave; Watchman Franchise Expansion.
NVCR drivers: New-indication launches (Optune Pax and Lua); International expansion and reimbursement wins.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most immediate concern is a run of setbacks in 2026. For NVCR, novoCure remains GAAP unprofitable (a trailing net loss of about $149 million) and depends on new launches converting into durable revenue, which is not guaranteed.

BSX or NVCR: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BSX if you believe its drivers more; NVCR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BSX and NVCR guides.

BSX vs NVCR: the full fundamentals

BSX. Boston Scientific's trailing P/E of roughly 18x and forward multiple near 13x are far below the sustained premium the stock carried during its high-growth phase. The compression followed a decline of about 55% over the past year, while the S&P 500 rose about 17%, driven by slowing growth, repeated outlook cuts, and the September cybersecurity disruption. Third-quarter results are due October 28, 2026, with consensus near $0.74 to $0.76 of adjusted EPS on revenue of about $5.1 billion, and the analyst mean target of about $59 sits well above the $44.06 share price, so the debate is whether the lower multiple reflects fair concern about decelerating growth or an over-correction.

NVCR. NovoCure trades at about 2.3 times trailing sales as a mid-teens-growth medical device company that is still not GAAP profitable, so it is valued more on revenue and future-indication optionality than on earnings. The Q1 2026 loss was amplified by a roughly $43 million one-time share-based-comp charge linked to the Optune Pax approval, while Q2 narrowed to about $16 million. About $441 million in cash against about $233 million of debt gives operating runway while the newer launches scale; Q3 2026 results are due October 29, with consensus EPS of about -$0.23.

Headline figures (approximate, October 2026): BSX shows revenue (ttm) ~$21 billion (+7.5% YoY in Q2 2026), revenue (fy 2025) ~$20.1 billion, net income (ttm) ~$3.7 billion (profit margin ~17.5%), adjusted eps (q2 2026) $0.86 vs $0.83 est.; NVCR shows revenue (ttm) ~$699M, revenue (q2 2026) ~$184M (up ~16% YoY), revenue (2026 consensus) ~$726M, gross margin (ttm) ~76%.

The bottom line: BSX vs NVCR

BSX and NVCR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BSX and NVCR exposure against your real portfolio. It is not an investment adviser.

Wondering how BSX or NVCR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Investing in Boston Scientific Corporation with AI

Connect the broker you already use and ask Walnut's AI how BSX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does BSX fit me?

FAQ

What is the difference between BSX and NVCR?

Is BSX or NVCR the better stock?

Neither is universally better. BSX is the larger incumbent; NVCR is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BSX or NVCR?

On forward P/E (as of October 2026), BSX trades at 13.15x and NVCR at -17.45x, so NVCR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BSX and NVCR?

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BSX vs NVCR?

BSX: The most immediate concern is a run of setbacks in 2026. Management lowered its profit outlook in July on weaker Watchman demand and US electrophysiology share losses, then in September said a cybersecurity incident had disrupted manufacturing and order shipments and that it was unlikely to meet its third-quarter and full-year sales and adjusted earnings forecasts. In October it recalled 262,686 Imager II angiographic catheters because the tip may fracture or detach during use, a reminder of the product-recall and safety-signal risk inherent to medical devices. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could further erode Boston Scientific's early PFA share and pressure pricing. Brokers including Baird, Truist and Mizuho trimmed price targets in mid-October 2026. Foreign exchange swings, hospital capital-spending cycles, reimbursement or regulatory changes, about $12.6 billion of debt, and integration risk from the company's acquisition strategy each add uncertainty. NVCR: NovoCure remains GAAP unprofitable (a trailing net loss of about $149 million) and depends on new launches converting into durable revenue, which is not guaranteed. Its Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary overall-survival endpoint, a reminder that clinical bets can disappoint and that the mature glioblastoma base offers limited upside. Reimbursement decisions, physician adoption of an unfamiliar device modality, and competition from drug-based oncology standards of care all create uncertainty. In September 2026 the company disclosed a cybersecurity incident that exposed patient data, which adds regulatory and reputational risk. The stock has been volatile, falling about 16% in the month to October 16, 2026 and sitting far below its historical highs, and heavy reliance on a single technology platform concentrates risk. Currency swings that recently helped revenue can also reverse.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BSX or NVCR; figures are approximate and dated (as of October 2026). Verify current data before investing.